University of California-Los Angeles
Izak Faiena graduated from the Albert Einstein College of Medicine with Alpha Omega Alpha honors. He then completed his urology residency at Rutgers Medical School where he received multiple research awards for his work in prostate and bladder cancer. He is currently completing a urologic oncology fellowship as well as a Master’s in clinical research at the UCLA Institute of Urologic Oncology and the Clinical and Translational Science Institute. His research focus has been on translational immuno-oncology and clinical trials. In his main study titled, Immune pathway changes pre and post checkpoint inhibitor therapy in metastatic urothelial carcinoma, aims at elucidating important immune factors affecting response to immune checkpoint inhibitors in patients with metastatic urothelial carcinoma who progressed on those treatments. In addition, he is finalizing a phase I trial of a DC-vaccine trial targeting CAIX in patients with metastatic renal cell carcinoma, which was recently presented at GU ASCO, and for which he received the Merit Award. Important corollary studies are underway to understand the immune reactivity of the vaccine therapy, and the immune response in the study cohort. This will inform refining the treatment protocol and perhaps provide some evidence for combination approaches with immune checkpoint inhibitors.